| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.01 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | 0.082 | 0.02 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | -0.09 | 0.02 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.077 | 0.02 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | -0.075 | 0.02 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.02 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.086 | 0.02 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | 0.074 | 0.02 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.03 |